

August 31, 2016


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (DE-141)	GLESATINIB
PRONUNCIATION	gle sa' ti nib
THERAPEUTIC CLAIM	Treatment of cancer

CHEMICAL NAMES

1. Benzeneacetamide, 4-fluoro-*N*-[[[3-fluoro-4-[[2-[5-[[2-methoxyethyl)amino]methyl]-2-pyridinyl]thieno[3,2-*b*]pyridin-7-yl]oxy]phenyl]amino]thioxomethyl]-
2. *N*-[(3-fluoro-4-[[2-(5-[(2-methoxyethyl)amino]methyl)pyridin-2-yl]thieno[3,2-*b*]pyridin-7-yl]oxy}phenyl)carbamothioyl]-2-(4-fluorophenyl)acetamide

STRUCTURAL FORMULA



MOLECULAR FORMULA	C ₃₁ H ₂₇ F ₂ N ₅ O ₃ S ₂
MOLECULAR WEIGHT	619.7
TRADEMARK	None as yet
SPONSOR	Mirati Therapeutics
CODE DESIGNATIONS	MGCD265, MG90265, MG90265H9, MG90265X, MG90265gly
<u>CAS</u> REGISTRY NUMBER	936694-12-1
UNII	7Q29OXD98N
WHO NUMBER	10217

gbk